Share on LinkedInShare on LinkedIn

ARTICLE · 22 JANUARY 2025

Timing Is Everything: Risks Of Delayed Patent List Submission In Canada

Torys
Torys
Contributor
Torys

Torys

Torys LLP is an international business law firm that works with clients who expect the best advice...

View firm profile
Explore more from Torys

In EMD Serono v The Minister of Health and Apotex, the Federal Court of Canada determined that the relevant date for assessing whether a patent must be addressed by a "second person"...

CanadaIntellectual Property

In EMD Serono v The Minister of Health and Apotex, the Federal Court of Canada determined that the relevant date for assessing whether a patent must be addressed by a "second person" who seeks to market a generic version of a patented drug is the date the patent is listed on the patent register by the Minister of Health (Minister), rather than the date the patent is submitted for listing by the "first person" (i.e. the innovative drug manufacturer).

What you need to know

  • A "second person" who seeks to market a generic version of a patented drug must address patents listed on the Health Canada patent register (the Register), the Canadian equivalent of the U.S. "Orange Book" for pharmaceutical patents1.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from